• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Supplement containing unlisted ED drug is recalled by manufacturer

Article

The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.

The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.

During the voluntary recall process, the manufacturer discovered a counterfeit of its product on the market. Both Liviro3 and the counterfeit supplement are undergoing renewed independent testing.

A bulletin issued by FDA cautions consumers who have either the genuine or counterfeit product in their possession to stop using it immediately and to contact their physician if they have experienced any problem that may be related to using either product.

Serious adverse events stemming from the use of Ebek’s Liviro3 or counterfeit Liviro3 should be reported to FDA’s MedWatch Adverse Event Reporting program online (www.fda.gov/MedWatch/report.htm) or by calling 800-FDA-1088.

Related Videos
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA helix | Image Credit: © Siarhei - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.